Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.50 |
| ▸ | RARB | P10826 | 2/20 | 0.50 |
| ▸ | RARG | P13631 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | RARA | P10276 | 1/20 | 0.41 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA3 | P07451 | 2/20 | 0.41 |
| ▸ | CA6 | P23280 | 2/20 | 0.41 |
| ▸ | CA5A | P35218 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL254959 | 0.92 | APP (0.61) | APPRARBRARGMAPTTSHR | |
| SCHEMBL2679567 | 0.89 | TSHR (0.60) | RARBRARGTSHRTP53PTPN11 | |
| SCHEMBL19262699 | 0.84 | PARP10 (0.55) | APPMAPTTSHRCYP3A4CA1 | |
| SCHEMBL402852 | 0.83 | TSHR (0.54) | APPRARBRARGTSHRTP53 | |
| Aminobenzoic Acid SCHEMBL8249 | 0.82 | TSHR (0.71) | MAPTTSHRTP53SRD5A2CA1 | |
| Terephthalic Acid SCHEMBL7648718 | 0.82 | TSHR (0.71) | MAPTTSHRTP53SRD5A2CA1 | |
| Terephthalic Acid SCHEMBL9717815 | 0.82 | TSHR (0.71) | MAPTTSHRTP53SRD5A2CA1 | |
| Aminobenzoic Acid SCHEMBL1768920 | 0.82 | TSHR (0.71) | MAPTTSHRTP53SRD5A2CA1 | |
| Aminobenzoic Acid SCHEMBL25326411 | 0.80 | TSHR (0.67) | MAPTTSHRTP53SRD5A2CA1 | |
| Aminobenzoic Acid SCHEMBL11038536 | 0.80 | TSHR (0.67) | MAPTTSHRTP53SRD5A2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425447-A1 | BENZOYLGLYCINE DERIVATIVES AND METHODS OF MAKING AND USING SAME | UNIV DUKE (US) | 2024-12-26 | — | — | US | disclosed |
| US-12103904-B2 | Benzoylglycine derivatives and methods of making and using same | DUKE UNIVERSITY (US) | 2024-10-01 | — | — | US | disclosed |
| EP-4286001-A2 | BENZOYLGLYCINE DERIVATIVES AND METHODS OF MAKING AND USING SAME | Duke University (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-3448375-B1 | BENZOYLGLYCINE DERIVATIVES AND METHODS OF MAKING AND USING SAME | UNIV DUKE (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-3374350-B1 | HYDROXYPYRIDINONE AND HYDROXYPYRIMIDINONE BASED COMPOUNDS FOR TREATING BACTERIAL INFECTIONS | FORGE THERAPEUTICS INC (US) | 2022-01-05 | — | — | EP | disclosed |
| EP-3374350-B1 | HYDROXYPYRIDINONE AND HYDROXYPYRIMIDINONE BASED COMPOUNDS FOR TREATING BACTERIAL INFECTIONS | FORGE THERAPEUTICS INC (US) | 2022-01-05 | — | — | EP | disclosed |
| US-20210206715-A1 | Benzoylglycine Derivatives and Methods of Making and Using Same | DUKE UNIVERSITY (US) | 2021-07-08 | — | — | US | disclosed |
| US-20210206715-A1 | Benzoylglycine Derivatives and Methods of Making and Using Same | DUKE UNIVERSITY (US) | 2021-07-08 | — | — | US | disclosed |
| US-11034649-B2 | Benzoylglycine derivatives and methods of making and using same | DUKE UNIVERSITY (US) | 2021-06-15 | — | — | US | disclosed |
| US-11034649-B2 | Benzoylglycine derivatives and methods of making and using same | DUKE UNIVERSITY (US) | 2021-06-15 | — | — | US | disclosed |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070244197-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244197-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244197-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2007-10-18 | — | — | US | disclosed |
| US-20060154988-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2006-07-13 | — | — | US | disclosed |
| US-20040229955-A1 | intracellular inhibition of bacterial polypeptide deformylase in gramnegative bacteria, | UNIVERSITY OF WASHINGTON | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244197-A1 | Antibacterial agents | MRPL21, SI, PGLS | APP 4303/4885RARB 1893/4885RARG 2443/4885 |
| US-20040229955-A1 | intracellular inhibition of bacterial polypeptide deformylase in gramnegative bacteria, | PDF, DDOST, MRPL21 | APP 3766/4885RARB 2971/4885RARG 3549/4885 |
| US-20210206715-A1 | Benzoylglycine Derivatives and Methods of Making and Using Same | B3GAT3, GLO1, GLMN | APP 4521/4885RARB 3367/4885RARG 1927/4885 |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | APP 4303/4885RARB 1893/4885RARG 2443/4885 |
| US-11034649-B2 | Benzoylglycine derivatives and methods of making and using same | B3GAT3, GLO1, GLMN | APP 4521/4885RARB 3367/4885RARG 1927/4885 |
| US-20240425447-A1 | BENZOYLGLYCINE DERIVATIVES AND METHODS OF MAKING AND USING SAME | BPGM, B3GAT3, GLMN | APP 4572/4885RARB 3899/4885RARG 2717/4885 |
| US-20060154988-A1 | Antibacterial agents | MRPL21, SI, PGLS | APP 4303/4885RARB 1893/4885RARG 2443/4885 |
| US-12103904-B2 | Benzoylglycine derivatives and methods of making and using same | B3GAT3, GLO1, GLMN | APP 4521/4885RARB 3367/4885RARG 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.